A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MUNOZ-MARTINEZ, Sergio et al. Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. Liver international, v. 42, n. 8, p. 1891-1901, 2022Tradução . . Disponível em: https://doi.org/10.1111/liv.15320. Acesso em: 05 jun. 2024.
APA
Munoz-martinez, S., Sapena, V., Forner, A., Bruix, J., Sanduzzi-zamparelli, M., Rios, J., et al. (2022). Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. Liver international, 42( 8), 1891-1901. doi:10.1111/liv.15320
NLM
Munoz-martinez S, Sapena V, Forner A, Bruix J, Sanduzzi-zamparelli M, Rios J, Bouattour M, El-kassas M, Leal CRG, Mocan T, Carrilho FJ. Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study [Internet]. Liver international. 2022 ; 42( 8): 1891-1901.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1111/liv.15320
Vancouver
Munoz-martinez S, Sapena V, Forner A, Bruix J, Sanduzzi-zamparelli M, Rios J, Bouattour M, El-kassas M, Leal CRG, Mocan T, Carrilho FJ. Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study [Internet]. Liver international. 2022 ; 42( 8): 1891-1901.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1111/liv.15320
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ZHU, Andrew X. et al. Search: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology, v. 33, n. 6, p. 559-566, 2015Tradução . . Disponível em: https://doi.org/10.1200/JCO.2013.53.7746. Acesso em: 05 jun. 2024.
APA
Zhu, A. X., Rosmorduc, O., Evans, T. R. J., Ross, P. J., Santoro, A., Carrilho, F. J., et al. (2015). Search: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology, 33( 6), 559-566. doi:10.1200/JCO.2013.53.7746
NLM
Zhu AX, Rosmorduc O, Evans TRJ, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre M-A, Jensen M, Meinhardt G, Kang YK. Search: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma [Internet]. Journal of Clinical Oncology. 2015 ; 33( 6): 559-566.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1200/JCO.2013.53.7746
Vancouver
Zhu AX, Rosmorduc O, Evans TRJ, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre M-A, Jensen M, Meinhardt G, Kang YK. Search: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma [Internet]. Journal of Clinical Oncology. 2015 ; 33( 6): 559-566.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1200/JCO.2013.53.7746
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
POYNARD, Thierry et al. Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: A randomized study. Journal of hepatology, v. 58, n. 3, p. 452-459, 2013Tradução . . Disponível em: https://doi.org/10.1016/j.jhep.2012.11.001. Acesso em: 05 jun. 2024.
APA
Poynard, T., Bruix, J., Schiff, E. R., Diago, M., Berg, T., Moreno-Otero, R., et al. (2013). Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: A randomized study. Journal of hepatology, 58( 3), 452-459. doi:10.1016/j.jhep.2012.11.001
NLM
Poynard T, Bruix J, Schiff ER, Diago M, Berg T, Moreno-Otero R, Lyra AC, Carrilho F, Griffel LH, Boparai N, Jiang R, Burroughs M, Brass CA, Albrecht JK. Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: A randomized study [Internet]. Journal of hepatology. 2013 ; 58( 3): 452-459.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1016/j.jhep.2012.11.001
Vancouver
Poynard T, Bruix J, Schiff ER, Diago M, Berg T, Moreno-Otero R, Lyra AC, Carrilho F, Griffel LH, Boparai N, Jiang R, Burroughs M, Brass CA, Albrecht JK. Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: A randomized study [Internet]. Journal of hepatology. 2013 ; 58( 3): 452-459.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1016/j.jhep.2012.11.001
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
POYNARD, Thierry et al. Fibrotest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program. Journal of hepatology, v. 54, n. 2, p. 227-235, 2011Tradução . . Disponível em: https://doi.org/10.1016/j.jhep.2010.06.038. Acesso em: 05 jun. 2024.
APA
Poynard, T., Munteanu, M., Colombo, M., Bruix, J., Schiff, E., Terg, R., et al. (2011). Fibrotest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program. Journal of hepatology, 54( 2), 227-235. doi:10.1016/j.jhep.2010.06.038
NLM
Poynard T, Munteanu M, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho FJ, Schmidt W, Berg T, Mcgarrity T, Heathcote EJ, Gonçales F, Diago M, Craxi A, Silva M, Boparai N, Griffel L, Burroughs M, Brass C, Albrecht J. Fibrotest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program [Internet]. Journal of hepatology. 2011 ; 54( 2): 227-235.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1016/j.jhep.2010.06.038
Vancouver
Poynard T, Munteanu M, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho FJ, Schmidt W, Berg T, Mcgarrity T, Heathcote EJ, Gonçales F, Diago M, Craxi A, Silva M, Boparai N, Griffel L, Burroughs M, Brass C, Albrecht J. Fibrotest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program [Internet]. Journal of hepatology. 2011 ; 54( 2): 227-235.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1016/j.jhep.2010.06.038
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
POYNARD, Thierry et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/rivavirin therapy. Gastroenterology, n. 5, p. 1618-1628, 2009Tradução . . Disponível em: http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6WFX-4VF56S3-1-7&_cdi=6806&_user=5674931&_orig=browse&_coverDate=05%2F31%2F2009&_sk=998639994&view=c&wchp=dGLzVtb-zSkzk&md5=e505ce4c1a8680184d2da5e5f7f7b20e&ie=/sdarticle.pdf. Acesso em: 05 jun. 2024.
APA
Poynard, T., Colombo, M., Bruix, J., Schiff, E., Terg, R., Flamm, S., et al. (2009). Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/rivavirin therapy. Gastroenterology, ( 5), 1618-1628. Recuperado de http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6WFX-4VF56S3-1-7&_cdi=6806&_user=5674931&_orig=browse&_coverDate=05%2F31%2F2009&_sk=998639994&view=c&wchp=dGLzVtb-zSkzk&md5=e505ce4c1a8680184d2da5e5f7f7b20e&ie=/sdarticle.pdf
NLM
Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho FJ, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Gonçalves F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/rivavirin therapy [Internet]. Gastroenterology. 2009 ;( 5): 1618-1628.[citado 2024 jun. 05 ] Available from: http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6WFX-4VF56S3-1-7&_cdi=6806&_user=5674931&_orig=browse&_coverDate=05%2F31%2F2009&_sk=998639994&view=c&wchp=dGLzVtb-zSkzk&md5=e505ce4c1a8680184d2da5e5f7f7b20e&ie=/sdarticle.pdf
Vancouver
Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho FJ, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Gonçalves F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/rivavirin therapy [Internet]. Gastroenterology. 2009 ;( 5): 1618-1628.[citado 2024 jun. 05 ] Available from: http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6WFX-4VF56S3-1-7&_cdi=6806&_user=5674931&_orig=browse&_coverDate=05%2F31%2F2009&_sk=998639994&view=c&wchp=dGLzVtb-zSkzk&md5=e505ce4c1a8680184d2da5e5f7f7b20e&ie=/sdarticle.pdf